Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

MRNS has been the topic of several other research reports. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Royal Bank of Canada dropped their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Monday, September 23rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $6.07.

Marinus Pharmaceuticals Stock Down 2.6 %

MRNS stock opened at $0.32 on Friday. The business’s fifty day simple moving average is $1.39 and its two-hundred day simple moving average is $1.37. Marinus Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $11.26. The firm has a market cap of $17.85 million, a price-to-earnings ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the prior year, the business posted ($0.61) EPS. Research analysts expect that Marinus Pharmaceuticals will post -1.92 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its holdings in Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after acquiring an additional 990,607 shares in the last quarter. Vanguard Group Inc. raised its position in Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares in the last quarter. abrdn plc increased its position in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after buying an additional 817,050 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth approximately $813,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.